Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) Cash-to-Debt : 0.05 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Mosaic ImmunoEngineering's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.05.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Mosaic ImmunoEngineering couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Mosaic ImmunoEngineering's Cash-to-Debt or its related term are showing as below:

CPMV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: No Debt Max: No Debt
Current: 0.05

During the past 13 years, Mosaic ImmunoEngineering's highest Cash to Debt Ratio was No Debt. The lowest was 0.05. And the median was No Debt.

CPMV's Cash-to-Debt is ranked worse than
95.94% of 1478 companies
in the Biotechnology industry
Industry Median: 7.005 vs CPMV: 0.05

Mosaic ImmunoEngineering Cash-to-Debt Historical Data

The historical data trend for Mosaic ImmunoEngineering's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mosaic ImmunoEngineering Cash-to-Debt Chart

Mosaic ImmunoEngineering Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.31

0.18

0.12

Mosaic ImmunoEngineering Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.10	0.28	0.20	0.12	0.05

Competitive Comparison of Mosaic ImmunoEngineering's Cash-to-Debt

For the Biotechnology subindustry, Mosaic ImmunoEngineering's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mosaic ImmunoEngineering's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's Cash-to-Debt falls into.

Mosaic ImmunoEngineering Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Mosaic ImmunoEngineering's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.156	/	(0	+	1.318)
	=	0.12

Mosaic ImmunoEngineering's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.065	/	(0	+	1.337)
	=	0.05

Mosaic ImmunoEngineering (OTCPK:CPMV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Mosaic ImmunoEngineering Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1537 South Novato Boulevard, Suite 5, Novato, CA, USA, 94947

Website

https://www.mosaicie.com

Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. The company has a single operating segment for the purposes of assessing performance and making operating decisions.

Executives

Robert Baffi	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University	10 percent owner	10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King	director, officer: President and CEO
Paul J Lytle	director, officer: EVP, Chief Financial Officer
Robert L Garnick	director	C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz	director, officer: Chief Scientific Officer	871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry	director	315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson	director
Donald E Schrock	director	C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau	officer: VP, Business Development	MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner	officer: Chief Executive Officer	MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers	officer: Chief Financial Officer	C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick	director	6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney	officer: CFO
Helmut Jr Falk	director